| 144 | 1 | 63 |
| 下载次数 | 被引频次 | 阅读次数 |
炎症性肠病（IBD）通常伴有慢性炎症，包括克罗恩病和溃疡性结肠炎，肠纤维化是其常见的并发症。近年来，随着与IBD和纤维化相关的各种研究逐步推进，肠道纤维化的发病机制、诊断和疾病管理取得了一定进展。其中，有研究着重于与纤维化过程、遗传和环境风险因素（如微生物群）相关的炎症非依赖性机制，也有通过生成新的体外和体内系统来研究纤维化。当前用于诊断纤维化IBD的成像技术包括断面成像，例如计算机断层扫描小肠造影（CTE）、磁共振小肠造影（MRE）、正电子发射断层扫描（PET）、单光子发射计算机断层扫描（SPECT）等。多种模式也显示出诊断纤维化过程的可能性，并在与分子显像剂结合使用时提供功能和形态信息。本文介绍了PET和SPECT等分子成像技术在肠纤维化领域的应用。
Abstract：Intestinal fibrosis is a common consequence of chronic inflammatory bowel disease(IBD) including Crohn's disease and ulcerative colitis. Research on inflammation-independent mechanisms connected to the fibrotic process, genetic and environmental risk factors such as microbiome as well as the generation of new in vitro and in vivo systems to study fibrogenesis have advanced the diagnosis and management of intestinal fibrosis. Current imaging techniques including computed tomography enterography(CTE),magnetic resonance enterography(MRE), single photon emission computed tomography(SPECT) and positron emission tomography(PET)demonstrate morphologically fibrotic IBD. We review the potential of SPECT and PET molecular imaging to provide functional information of intestinal fibrosis.
[1]Rieder F, Fiocchi C, Rogler G. Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases.Gastroenterology, 2017,152(2):340-350.e6.
[2]Pellino G, Pallante P, Selvaggi F. Novel biomarkers of fibrosis in Crohn’s disease. World J Gastrointest Pathophysiol, 2016,7(3):266-275.
[3]Higgins PD. Measurement of fibrosis in Crohn’s disease strictures with imaging and blood biomarkers to inform clinical decisions. Dig Dis, 2017,35(1-2):32-37.
[4]Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology, 2002,123(3):679-688.
[5]Sadler T, Bhasin JM, Xu Y, et al. Genome-wide analysis of DNA methylation and gene expression defines molecular characteristics of Crohn’s disease-associated fibrosis. Clin Epigenetics, 2016,8:30.
[6]Burke JP, Ferrante M, Dejaegher K, et al. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn’s disease. Inflamm Bowel Dis, 2008,14(9):1197-1204.
[7]Verspaget HW, Biemond I, Allaart CF, et al. Assessment of plasma fibronectin in Crohn’s disease. Hepatogastroenterology,1991,38(3):231-234.
[8]Vind I, Johansen JS, Price PA, et al. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol, 2003,38(6):599-605.
[9]Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum b FGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn’s disease. Inflamm Bowel Dis,2004,10(5):573-577.
[10]Nijhuis A, Biancheri P, Lewis A, et al. In Crohn’s disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. Clin Sci, 2014,127(5):341-350.
[11]Stidham RW, Wu J, Shi J, et al. Serum glycoproteome profiles for distinguishing intestinal fibrosis from inflammation in Crohn’s disease. PLoS One, 2017,12(1):e0170506.
[12]Rieder F. Managing intestinal fibrosis in patients with inflammatory bowel disease. Gastroenterol Hepatol, 2018,14(2):120-122.
[13]Allocca M, Fiorino G, Bonifacio C, et al. Noninvasive multimodal methods to differentiate inflamed vs fibrotic strictures in patients with Crohn’s disease. Clin Gastroenterol Hepatol, 2019,17(12):2397-2415.
[14]Catalano O, Maccioni F, Lauri C, et al. Hybrid imaging in Crohn’s disease:from SPECT/CT to PET/MR and new image interpretation criteria. Q J Nucl Med Mol Imaging, 2018,62(1):40-55.
[15]Stathaki MI, Koukouraki SI, Karkavitsas NS, et al. Role of scintigraphy in inflammatory bowel disease. World J Gastroenterol,2009,15(22):2693-2700.
[16]GE Healthcare. CeretecTMkit for the preparation of technetium Tc99 m exametazime injection:4789736.[2020-07-31]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019829s026lbl.pdf.
[17]de Vries EF, Roca M, Jamar F, et al. Guidelines for the labelling of leucocytes with99mTc-HMPAO. Eur J Nucl Med Mol Imaging, 2010,37(4):842-848.
[18]Arndt JW, Grootscholten MI, van Hogezand RA, et al.Inflammatory bowel disease activity assessment using technetium-99m-HMPAO leukocytes. Dig Dis Sci, 1997,42(2):387-393.
[19]Charron M, del Rosario FJ, Kocoshis SA. Pediatric inflammatory bowel disease:assessment with scintigraphy with99mTc white blood cells. Radiology, 1999,212(2):507-513.
[20]Biancone L, Schillaci O, Capoccetti F, et al. Technetium-99mHMPAO labeled leukocyte single photon emission computerized tomography(SPECT)for assessing Crohn’s disease extent and intestinal infiltration. Am J Gastroenterol, 2005,100(2):344-354.
[21]Kerry JE, Marshall C, Griffiths PA, et al. Comparison between Tc-HMPAO labelled white cells and Tc LeukoScan in the investigation of inflammatory bowel disease. Nucl Med Commun,2005,26(3):245-251.
[22]Aarntzen EH, Hermsen R, Drenth JP, et al.99mTc-CXCL8SPECT to monitor disease activity in inflammatory bowel disease. J Nucl Med, 2016,57(3):398-403.
[23]Annovazzi A, Biancone L, Caviglia R, et al.99mTc-interleukin-2and99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn’s disease. Eur J Nucl Med Mol Imaging, 2003,30(3):374-382.
[24]Signore A, Chianelli M, Annovazzi A, et al.123I-interleukin-2scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn’s disease. J Nucl Med, 2000,41(2):242-249.
[25]Das CJ, Makharia G, Kumar R, et al. PET-CT enteroclysis:a new technique for evaluation of inflammatory diseases of the intestine. Eur J Nucl Med Mol Imaging, 2007,34(12):2106-2114.
[26]Ahmadi A, Li Q, Muller K, et al. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-Dglucose positron emission tomography and computed tomography enterography in active Crohn’s disease. Inflamm Bowel Dis,2010,16(6):974-981.
[27]Glaudemans AW, de Vries EF, Galli F, et al. The use of18FFDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol, 2013,2013:623036.
[28]Lapp RT, Spier BJ, Perlman SB, et al. Clinical utility of positron emission tomography/computed tomography in inflammatory bowel disease. Mol Imaging Biol, 2011,13(3):573-576.
[29]Spier BJ, Perlman SB, Jaskowiak CJ, et al. PET/CT in the evaluation of inflammatory bowel disease:studies in patients before and after treatment. Mol Imaging Biol, 2010,12(1):85-88.
[30]Saboury B, Salavati A, Brothers A, et al. FDG PET/CT in Crohn’s disease:correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging, 2014, 41(4):605-614.
[31]Catalano OA, Wu V, Mahmood U, et al. Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease. Am J Nucl Med Mol Imaging, 2018,8(1):62-69.
[32]Catalano OA, Gee MS, Nicolai E, et al. Evaluation of quantitative PET/MR enterography biomarkers for discrimination of inflammatory strictures from fibrotic strictures in Crohn disease.Radiology, 2016,278(3):792-800.
[33]Ozülker T, Ozülker F, Mert M, et al. Clearance of the high intestinal18F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging, 2010,37(5):1011-1017.
[34]Le Fur M, Zhou IY, Catalano O, et al. Toward molecular imaging of intestinal pathology. Inflamm Bowel Dis, 2020,26(10):1470-1484.
[35]Li F, Song ZJ, Li QH, et al. Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrin αvβ3expression with SPECT in rat. Hepatology, 2011,54(3):1020-1030.
[36]Kuijpers BH, Groothuys S, Soede AC, et al. Preparation and evaluation of glycosylated arginine-glycine-aspartate(RGD)derivatives for integrin targeting. Bioconjug Chem, 2007,18(6):1847-1854.
[37]Patsenker E, Popov Y, Stickel F, et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology, 2009,50(5):1501-1511.
[38]Hatori A, Yui J, Xie L, et al. Utility of translocator protein(18 k Da)as a molecular imaging biomarker to monitor the progression of liver fibrosis. Sci Rep, 2015,5:17327.
[39]Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg-Gly-Asp(RGD)peptide radioligand18FAH111585 in breast cancer patients. J Nucl Med, 2008,49(6):879-886.
[40]Chen DL, Schiebler ML, Goo JM, et al. PET imaging approaches for inflammatory lung diseases:current concepts and future directions. Eur J Radiol, 2017,86:371-376.
[41]Caravan P, Das B, Dumas S, et al. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Engl, 2007,46(43):8171-8173.
[42]Caravan P, Yang Y, Zachariah R, et al. Molecular magnetic resonance imaging of pulmonary fibrosis in mice. Am J Respir Cell Mol Biol, 2013,49(6):1120-1126.
[43]Li ZL, Lu BL, Lin JJ, et al. A type I collagen-targeted MR imaging probe for staging fibrosis in Crohn’s disease. Front Mol Biosci, 2021,8:762355.
[44]Baues M, Dasgupta A, Ehling J, et al. Fibrosis imaging:current concepts and future directions. Adv Drug Deliv Rev, 2017,121:9-26.
[45]Désogère P, Tapias LF, Hariri LP, et al. Type I collagentargeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med, 2017,9(384):eaaf4696.
基本信息:
中图分类号:R574;R817.4
引用信息:
[1]李周雷,谭婉红,孟霁昕,等.分子影像学与纤维化（五）：肠纤维化显像之二[J].影像诊断与介入放射学,2022,31(03):222-225.
2022-06-25
2022-06-25